Literature DB >> 28212496

Antipsychotic Use in Dementia.

Julia Kirkham1, Chelsea Sherman1, Clive Velkers1, Colleen Maxwell2, Sudeep Gill3, Paula Rochon4, Dallas Seitz1.   

Abstract

Antipsychotics are necessary for many older adults to treat major mental illnesses or reduce distressing psychiatric symptoms. Current controversy exists over the role of antipsychotics in the management of neuropsychiatric symptoms (NPS) in persons with dementia. Although some NPS may be appropriately and safely treated with antipsychotics, a fine balance must be achieved between the benefits of these medications, which are often modest, and adverse events, which may have significant consequences. Approximately one-third of all persons with dementia are currently prescribed antipsychotic medications, and there is significant variation in the use of antipsychotics across care settings and providers. Reducing the inappropriate or unnecessary use of antipsychotics among persons with dementia has been the focus of increasing attention owing to better awareness of the potential problems associated with these medications. Several approaches can be used to curb the use of antipsychotics among persons with dementia, including policy or regulatory changes, public reporting, and educational outreach. Recently, there has been encouraging evidence of a downward trend in the use of antipsychotics in many long-term care settings, although prescribing rates are still higher than what is likely optimal. Although reducing the inappropriate use of antipsychotics is a complex task, psychiatrists can play an important role via the provision of clinical care and research evidence, contributing to improved care of persons with dementia in Canada and elsewhere.

Entities:  

Keywords:  adverse events; antipsychotics; dementia; long-term care; quality improvement; quality of care

Mesh:

Substances:

Year:  2016        PMID: 28212496      PMCID: PMC5317021          DOI: 10.1177/0706743716673321

Source DB:  PubMed          Journal:  Can J Psychiatry        ISSN: 0706-7437            Impact factor:   4.356


  91 in total

1.  Living well with dementia--development of the national dementia strategy for England.

Authors:  Sube Banerjee
Journal:  Int J Geriatr Psychiatry       Date:  2010-09       Impact factor: 3.485

2.  The OBRA-87 nursing home regulations and implementation of the Resident Assessment Instrument: effects on process quality.

Authors:  C Hawes; V Mor; C D Phillips; B E Fries; J N Morris; E Steele-Friedlob; A M Greene; M Nennstiel
Journal:  J Am Geriatr Soc       Date:  1997-08       Impact factor: 5.562

3.  Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD.

Authors:  Cheryl L P Vigen; Wendy J Mack; Richard S E Keefe; Mary Sano; David L Sultzer; T Scott Stroup; Karen S Dagerman; John K Hsiao; Barry D Lebowitz; Constantine G Lyketsos; Pierre N Tariot; Ling Zheng; Lon S Schneider
Journal:  Am J Psychiatry       Date:  2011-05-15       Impact factor: 18.112

4.  The American Psychiatric Association Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia.

Authors:  Victor I Reus; Laura J Fochtmann; A Evan Eyler; Donald M Hilty; Marcela Horvitz-Lennon; Michael D Jibson; Oscar L Lopez; Jane Mahoney; Jagoda Pasic; Zaldy S Tan; Cheryl D Wills; Richard Rhoads; Joel Yager
Journal:  Am J Psychiatry       Date:  2016-05-01       Impact factor: 18.112

5.  Mental illness and psychotropic medication use in the nursing home.

Authors:  G Arling; B J Ryther; T Collins; D Zimmerman
Journal:  J Aging Health       Date:  1991-11

6.  Prevalence and correlates of psychotropic drug use in Dutch nursing-home patients with dementia.

Authors:  Renate M Nijk; Sytse U Zuidema; Raymond T C M Koopmans
Journal:  Int Psychogeriatr       Date:  2009-04-16       Impact factor: 3.878

7.  Trends in Psychotropic Dispensing Among Older Adults with Dementia Living in Long-Term Care Facilities: 2004-2013.

Authors:  Akshya Vasudev; Salimah Z Shariff; Kuan Liu; Amer M Burhan; Nathan Herrmann; Sean Leonard; Muhammad Mamdani
Journal:  Am J Geriatr Psychiatry       Date:  2015-07-17       Impact factor: 4.105

8.  Variation in nursing home antipsychotic prescribing rates.

Authors:  Paula A Rochon; Therese A Stukel; Susan E Bronskill; Tara Gomes; Kathy Sykora; Walter P Wodchis; Michael Hillmer; Alexander Kopp; Jerry H Gurwitz; Geoffrey M Anderson
Journal:  Arch Intern Med       Date:  2007-04-09

Review 9.  Interventions to reduce inappropriate prescribing of antipsychotic medications in people with dementia resident in care homes: a systematic review.

Authors:  Jo Thompson Coon; Rebecca Abbott; Morwenna Rogers; Rebecca Whear; Stephen Pearson; Iain Lang; Nick Cartmell; Ken Stein
Journal:  J Am Med Dir Assoc       Date:  2014-08-08       Impact factor: 4.669

10.  Recommendations of the 4th Canadian Consensus Conference on the Diagnosis and Treatment of Dementia (CCCDTD4).

Authors:  Serge Gauthier; Christopher Patterson; Howard Chertkow; Michael Gordon; Nathan Herrmann; Kenneth Rockwood; Pedro Rosa-Neto; Jean-Paul Soucy
Journal:  Can Geriatr J       Date:  2012-12-04
View more
  22 in total

1.  Detecting and Managing Neuropsychiatric Symptoms in Dementia.

Authors:  Andrea Iaboni; Mark J Rapoport
Journal:  Can J Psychiatry       Date:  2017-03       Impact factor: 4.356

2.  Impact of the Quebec Alzheimer Plan on the detection and management of Alzheimer disease and other neurocognitive disorders in primary health care: a retrospective study.

Authors:  Isabelle Vedel; Nadia Sourial; Genevieve Arsenault-Lapierre; Claire Godard-Sebillotte; Howard Bergman
Journal:  CMAJ Open       Date:  2019-06-14

3.  Incidence and Outcomes of SARS-CoV-2 Infection in Older Adults Living with Dementia: A Population-Based Cohort Study.

Authors:  Silvia Cascini; Nera Agabiti; Claudia Marino; Anna Acampora; Maria Balducci; Enrico Calandrini; Marina Davoli; Anna Maria Bargagli
Journal:  J Alzheimers Dis       Date:  2022       Impact factor: 4.160

4.  Implementation and Evaluation of an Acute Care Multicomponent Intervention for Dementia-Related Behavioral Expressions.

Authors:  Andrea Gilmore-Bykovskyi; Megan Markart; Khloe Imig; Karen Hunt; Dave Murray; Laura Block; Jennifer Dhein
Journal:  J Gerontol Nurs       Date:  2021-09-01       Impact factor: 1.436

Review 5.  Emotional and Neuropsychiatric Disorders Associated with Alzheimer's Disease.

Authors:  Kenneth M Heilman; Stephen E Nadeau
Journal:  Neurotherapeutics       Date:  2022-01-10       Impact factor: 6.088

6.  Antipsychotic Use With and Without Comorbid Psychiatric Diagnosis Among Adults with Intellectual and Developmental Disabilities.

Authors:  Yona Lunsky; Wayne Khuu; Mina Tadrous; Simone Vigod; Virginie Cobigo; Tara Gomes
Journal:  Can J Psychiatry       Date:  2017-08-22       Impact factor: 4.356

7.  Effect of person-centred care on antipsychotic drug use in nursing homes (EPCentCare): a cluster-randomised controlled trial.

Authors:  Christin Richter; Almuth Berg; Henriette Langner; Gabriele Meyer; Sascha Köpke; Katrin Balzer; Eva-Maria Wolschon; Katharina Silies; Andreas Sönnichsen; Susanne Löscher; Burkhard Haastert; Andrea Icks; Ursula Wolf; Steffen Fleischer
Journal:  Age Ageing       Date:  2019-05-01       Impact factor: 10.668

8.  Assessment of Reported Comparative Effectiveness and Safety of Atypical Antipsychotics in the Treatment of Behavioral and Psychological Symptoms of Dementia: A Network Meta-analysis.

Authors:  Ismaeel Yunusa; Adnan Alsumali; Asabe E Garba; Quentin R Regestein; Tewodros Eguale
Journal:  JAMA Netw Open       Date:  2019-03-01

9.  Public reporting of antipsychotic prescribing in nursing homes: population-based interrupted time series analyses.

Authors:  Noah M Ivers; Monica Taljaard; Vasily Giannakeas; Catherine Reis; Evelyn Williams; Susan Bronskill
Journal:  BMJ Qual Saf       Date:  2018-07-30       Impact factor: 7.035

Review 10.  The Hyperactivity-Impulsivity-Irritiability-Disinhibition-Aggression-Agitation Domain in Alzheimer's Disease: Current Management and Future Directions.

Authors:  Rachel M Keszycki; Daniel W Fisher; Hongxin Dong
Journal:  Front Pharmacol       Date:  2019-09-27       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.